FAM86A Polyclonal antibody

• 

  WB analysis using 32472-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 32472-1-AP (FAM86A antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

FAM86A Polyclonal Antibody for WB, ELISA

Cat No. 32472-1-AP

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Synonyms

EC:2.1.1.-, EEF2KMT, eEF2-KMT, eEF2-lysine methyltransferase, Eukaryotic Elongation Factor 2 Lysine Methyltransferase

---

Tested Applications

• Positive WB detected in: MCF-7 cells

Recommended dilution

• Western Blot (WB): WB : 1:1000-1:4000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

32472-1-AP targets FAM86A in WB, ELISA applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: FAM86A fusion protein Ag38481
• Full Name: family with sequence similarity 86, member A
• Observed Molecular Weight: 38 kDa
• GenBank Accession Number: BC010084
• Gene Symbol: FAM86A
• Gene ID (NCBI): 196483
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity Purification
• UNIPROT ID: Q96G04
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

FAM86A is a class I lysine methyltransferase (KMT), belonging to the family of protein methyltransferases (KMTs), which produces trimethylation (K525me3) at the Lys525 site of eukaryotic translation elongation factor 2 (EEF2) and promotes the binding of eEF2 to ribosomes, thereby regulating the protein synthesis. (PMID: 38508183) FAM86A is expressed in a highly dependent manner in a variety of human cancer cell lines, suggesting that FAM86A may be a potential target for future anticancer therapy.